Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales

physicians prescribing VELCADE," said Christophe Bianchi, M.D., Executive Vice President, Commercial, Millennium. "The future of VELCADE is even more exciting as we look to expand into front-line multiple myeloma with several combinations that have the potential to deliver the strongest long- term survival for patients."

-- Phase III VISTA Trial in Front-Line Multiple Myeloma (MM) -- The

Company announced that the results of the large, randomized, Phase III

VISTA trial in patients with newly diagnosed MM showed that the therapy

of VELCADE, melphalan and prednisone demonstrated a highly

statistically significant improvement, compared with melphalan and

prednisone alone, across all efficacy endpoints, including time to

progression, complete remission rate, progression free survival and

overall survival. Side effects were manageable and included those seen

in previous VELCADE trials. Based on these positive data, the control

arm of the trial was stopped early to allow patients still being

treated with melphalan and prednisone to have VELCADE added to their

therapy. The Company now expects to file a supplementary new drug

application (sNDA) for use of VELCADE in patients with newly diagnosed

MM in December 2007.

-- Compendia Listing in Front-Line MM -- In October 2007, the national

compendia organization DrugPoints Systems included VELCADE as a

recommended therapy for use in newly diagnosed multiple myeloma


-- Label Expansion in MM -- In October 2007, the U.S. Food and Drug

Administration (FDA) granted approval for VELCADE use, without dose

adjustments, in patients with impaired kidney function, including those

requiring dialysis. Impaired kidney function is a common complication

related to MM, affecting approximately 30 percent of patients at


SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
(Date:10/8/2015)... , October 8, 2015 ... --> Global Biologics and Biosimilars industry . ... report "Global Biologics and Biosimilars Industry 2015 Deep ... and Forecast" is a professional and depth research ... . ) , --> ...
(Date:10/8/2015)... , Oct. 8, 2015  Today the Wyss ... the launch of its start-up company Opsonix Inc. ... between Harvard,s Office of Technology Development (OTD) ... Wyss-designed sepsis therapy for clinical use. ... at least a million people every year in the ...
(Date:10/7/2015)... PUNE, India , October 8, 2015 ... --> Medical biotechnology accounts for ... use of bioinformatics in drug discovery and ... with . ... --> On the basis of applications, ...
(Date:10/7/2015)... , Oct. 7, 2015  ContraVir Pharmaceuticals, Inc. ... biopharmaceutical company focused on the development and commercialization of ... underwritten public offering of 5,000,000 shares of its common ... of the Company,s common stock at a fixed combined ... common stock and warrants will be issued separately.  The ...
Breaking Biology Technology:
... a material in which an electric field can control the ... effect discovered by the Rutgers group can be extended to ... bits in ultra high-density data storage. The research appears in ... The researchers found the effect by studying the magnetic properties ...
... ROCKVILLE, Md., Aug. 22 A research team co-led by ... Institute for Genome Sciences (IGS), University of Maryland School of ... bean ( Ricinus communis ) genome in Nature Biotechnology ... IGS were co-lead authors on the paper describing the 4.5X ...
... Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using... -- BRUSSELS, August 19, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, Inc. ... that it has signed a contract with the Virginia ... the full range of sentences under the Department,s oversight. ... the Americas. "This contract with the Virginia DOC will ... US and advances our position as a trusted leader ...
(Date:10/2/2015)... , Oct. 02 2015 ... the "Enforcing the Law Using Biometrics" ... ) has announced the addition of the ... their offering. --> Research and Markets ... the "Enforcing the Law Using Biometrics" ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
Breaking Biology News(10 mins):
... Next week a British engineering team heads off to Antarctica ... collect water and sediment samples from a lake buried beneath ... the frontier of exploration, will yield new knowledge about the ... provide vital clues about the Earth,s past climate. Transporting ...
... the oceans of Earth were roamed by a very different ... swam at the top of the Triassic Period ocean food ... Mark McMenamin took a look at some of their remains ... and more cunning sea monster that preyed on ichthyosaurs: a ...
... researchers along with collaborators from Massachusetts Institute ... found a way to block, in an animal ... disease conditions. In their report receiving early ... investigators describe using small interfering RNA technology to ...
Cached Biology News:
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: